Woodford Investment Management Ltd Sells 50,810 Shares of Prothena Corporation PLC (PRTA)

Woodford Investment Management Ltd cut its stake in shares of Prothena Corporation PLC (NASDAQ:PRTA) by 0.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,349,614 shares of the biotechnology company’s stock after selling 50,810 shares during the quarter. Prothena Corporation PLC comprises about 33.9% of Woodford Investment Management Ltd’s investment portfolio, making the stock its largest position. Woodford Investment Management Ltd owned approximately 29.65% of Prothena Corporation PLC worth $557,568,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of PRTA. Principal Financial Group Inc. grew its stake in shares of Prothena Corporation PLC by 1.2% during the 1st quarter. Principal Financial Group Inc. now owns 6,528 shares of the biotechnology company’s stock worth $364,000 after purchasing an additional 77 shares during the period. Vanguard Group Inc. boosted its position in shares of Prothena Corporation PLC by 16.2% in the 1st quarter. Vanguard Group Inc. now owns 699,858 shares of the biotechnology company’s stock worth $39,045,000 after buying an additional 97,631 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Prothena Corporation PLC by 13.4% in the 1st quarter. Geode Capital Management LLC now owns 319,139 shares of the biotechnology company’s stock worth $17,804,000 after buying an additional 37,801 shares in the last quarter. BlackRock Inc. boosted its position in shares of Prothena Corporation PLC by 95,458.7% in the 1st quarter. BlackRock Inc. now owns 2,733,934 shares of the biotechnology company’s stock worth $152,526,000 after buying an additional 2,731,073 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Prothena Corporation PLC by 12.1% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 153,857 shares of the biotechnology company’s stock worth $8,584,000 after buying an additional 16,665 shares in the last quarter.

In other Prothena Corporation PLC news, Director Christopher S. Henney sold 900 shares of the stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $70.00, for a total value of $63,000.00. Following the completion of the sale, the director now owns 900 shares of the company’s stock, valued at $63,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Dennis J. Selkoe sold 3,500 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $64.17, for a total transaction of $224,595.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,424 shares of company stock valued at $1,922,787. Corporate insiders own 3.10% of the company’s stock.

Several equities research analysts recently commented on PRTA shares. ValuEngine upgraded shares of Prothena Corporation PLC from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Deutsche Bank AG set a $73.00 price objective on shares of Prothena Corporation PLC and gave the stock a “buy” rating in a research report on Monday, October 23rd. Zacks Investment Research upgraded shares of Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $66.00 target price on the stock in a report on Friday, August 11th. BidaskClub upgraded shares of Prothena Corporation PLC from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 19th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $79.00 target price on shares of Prothena Corporation PLC in a report on Thursday, September 28th. One equities research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $78.58.

Prothena Corporation PLC (PRTA) traded up $0.55 during midday trading on Monday, hitting $62.85. 66,741 shares of the stock were exchanged, compared to its average volume of 247,340. Prothena Corporation PLC has a one year low of $40.59 and a one year high of $70.00.

Prothena Corporation PLC (NASDAQ:PRTA) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.89) by $0.43. The business had revenue of $26.81 million for the quarter, compared to analyst estimates of $16.08 million. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 33.20%. The company’s revenue was up 7951.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.18) EPS. sell-side analysts forecast that Prothena Corporation PLC will post -4.51 earnings per share for the current year.

WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.com-unik.info/2017/11/06/woodford-investment-management-ltd-sells-50810-shares-of-prothena-corporation-plc-prta.html.

Prothena Corporation PLC Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Corporation PLC (NASDAQ:PRTA).

Institutional Ownership by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

What are top analysts saying about Prothena Corporation PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Prothena Corporation PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit